Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells

T M Astakhova1, G V Delone, Yu V Lyupina

  • 1Koltsov Institute for Developmental Biology, Russian Academy of Sciences.

Acta Naturae
|June 1, 2012
PubMed

Insights

Changes in liver proteasome forms, including increased expression of specific subunits, occur during early stages of liver disease and cancer development. The 19S proteasome activator may be a target for new anticancer drugs.

Area of Science:

  • Cell Biology
  • Biochemistry
  • Oncology

Background:

  • Proteasomes are crucial for protein degradation and peptide formation, regulating cellular processes.
  • Dysfunctional proteasomes are implicated in various pathologies, including carcinogenesis.
  • Understanding proteasome alterations during liver disease progression is vital for identifying therapeutic targets.

Purpose of the Study:

  • To investigate changes in liver proteasome forms during nodular regenerative hyperplasia, adenoma, and hepatocellular carcinoma development in mice.
  • To analyze the expression of proteasome subunits and their enzymatic activity in relation to liver carcinogenesis.
  • To identify potential therapeutic targets for liver cancer based on proteasome alterations.

Main Methods:

  • Western blot analysis to determine the relative content of various proteasome forms.
  • Assay of chymotrypsin-like proteasome activity using the Suc-LLVY-AMC substrate.
  • Induction of liver pathologies using Dipin treatment followed by partial liver resection in mice.

Main Results:

  • Proteasome pool alterations were observed early in nodular regenerative hyperplasia, with increased expression of constitutive (X/β5) and immune (LMP7/β5i, LMP2/β1i) subunits.
  • Total proteasome pool increased, while chymotrypsin-like activity decreased during disease progression, with more pronounced changes in hepatocellular carcinoma.
  • The 19S proteasome activator subunit Rpt6 was elevated in carcinoma, suggesting its role in malignant transformation.

Conclusions:

  • Nodular regenerative hyperplasia and adenomatosis represent pre-carcinogenic stages in liver disease.
  • Signaling pathways influencing proteasome subunit expression during carcinogenesis require further investigation.
  • The 19S proteasome activator presents a promising therapeutic target for developing novel anticancer drugs.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...